Efficacy and Safety of HCV-Treatment with Direct-Acting Antiviral Agents Interferon-Free, in Patients with Severe Renal Impairment in Clinical Practice

Objective. To determine the efficacy and safety of direct-acting antiviral agents (DAA) in patients with chronic HCV infection and UGT1A1*28 polymorphism. Materials and Methods. An open-label, non-randomized, observational study to assess efficacy and safety of DAA in patients (n = 143) with chronic hepatitis C (CHC) and liver cirrhosis and UGT1A1*28 polymorphism was performed. A total of 139 patients with chronic HCV infection were included in the efficacy analysis (absence of HCV RNA in blood by PCR) by the rate of sustained virologic response at week 12 (SVR12). Results. The SVR12 rate in patients with CHC and HCV-CP was 92.5% and 87.9%, respectively (p = 0.508), regardless of the presence of UGT1A1*28 polymorphism. The SVR12 rate in patients with chronic HCV infection and (TA)7/(TA)7 was 84.8%, with (TA)6/(TA)7 – 92.2% compared with (TA)6/ (TA)6 – 90,5% (p = 0.518). The rate of SVR12 in patients with CHC and (TA)7/(TA)7 or (TA)6/(TA)7 was 80% and 95%, respectively, with (TA)6/(TA)6 – 95.2%. The rate of SVR12 in patients with liver cirrhosis and (TA)7/(TA)7 or (TA)6/(TA)7 was 92.3% and 87.5%, respectively, with (TA)6/(TA)6 – 85.7%. The rate of SVR12 in patients with 12- and 24-week treatment duration was 88.2% and 96.6%, respectively (p = 0.30). As many as 96.2% of patients with the previous treatment with interferon and ribavirin had SVR12 compared to 88.5% of patients who have not previously taken antiviral drugs (p = 0.486). Grade 1 adverse events (AE) occurred in 24% of patients with chronic HCV infection treated with DAA; two patients developed Grade 4 AE. Conclusions. The treatment with DAA was shown to be effective and safe in patients with chronic HCV infection and UGT1A1*28 polymorphism.

Download Full-text

Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease

Nefrología (English Edition) ◽

10.1016/j.nefroe.2019.03.014 ◽

2020 ◽

Vol 40 (1) ◽

pp. 46-52 ◽

Cited By ~ 1

Author(s):

Ezequiel Ridruejo ◽

Rebeca Garcia-Agudo ◽

Manuel Mendizabal ◽

Sami Aoufi-Rabih ◽

Vivek Dixit ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Antiviral Agents ◽

Efficacy And Safety ◽

Direct Acting Antiviral ◽

Moderate Chronic Kidney Disease ◽

Direct Acting ◽

Direct Acting Antiviral Agents

Download Full-text

Relevance of Resistance Against Direct Acting Antiviral Agents in Hepatitis C Virus Infection – What Technology do we Really Need in Clinical Practice?

Current Hepatology Reports ◽

10.1007/s11901-013-0185-3 ◽

2013 ◽

Vol 12 (4) ◽

pp. 195-199

Author(s):

Sandra Ciesek ◽

Thomas Hahn

Keyword(s):

Clinical Practice ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Antiviral Agents ◽

Hepatitis C Virus Infection ◽

Direct Acting Antiviral ◽

Direct Acting ◽

Direct Acting Antiviral Agents

Download Full-text

6ER-010 Focus on hcv treatment based on second-generation direct-acting antiviral agents (daas-2): comparing national and local prescribing trends

10.1136/ejhpharm-2018-eahpconf.503 ◽

2018 ◽

Author(s):

C Inserra ◽

A Zovi ◽

V Scalzi ◽

L Zampogna ◽

S Vimercati ◽

...

Keyword(s):

Second Generation ◽

Antiviral Agents ◽

Hcv Treatment ◽

Direct Acting Antiviral ◽

Prescribing Trends ◽

Direct Acting ◽

Direct Acting Antiviral Agents

Download Full-text

Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection

Canadian Journal of Gastroenterology and Hepatology ◽

10.1155/2020/8872120 ◽

2020 ◽

Vol 2020 ◽

pp. 1-8

Author(s):

Yong-yu Mei ◽

You-ming Chen ◽

Yuan-kai Wu ◽

Xiao-hong Zhang ◽

Wen-xiong Xu

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virological Response ◽

Antiviral Agents ◽

Hcv Infection ◽

Efficacy And Safety ◽

Direct Acting Antiviral ◽

Direct Acting ◽

Direct Acting Antiviral Agents

Aims. The aim is to evaluate the efficacy and safety of Sofosbuvir- (SOF-) based direct-acting antiviral agents (DAAs) treatment for patients with genotype (GT) 3/6 hepatitis C virus (HCV) infection. Methods. Patients infected with GT 3/6 HCV and treated with SOF-based DAAs were enrolled in this prospective, open, single-center, and real-world study. Drugs included Sofosbuvir (SOF), Velpatasvir (VEL), Daclatasvir (DCV), and Ribavirin (RBV). The treatment regimens included SOF + RBV for 24 weeks, SOF + DCV ± RBV for 12/24 weeks, and SOF/VEL ± RBV for 12 weeks. Results. A total of 54 patients were included. Age was 42.5 ± 10.4 years. Baseline HCV RNA was 6.29 ± 0.89log10 IU/mL. The numbers of GT 3a, 3b, and 6a patients were 10, 12, and 32, respectively. The numbers of chronic hepatitis, compensated cirrhosis, and decompensated cirrhosis patients were 39, 9, and 6, respectively. In patients with chronic hepatitis C and liver cirrhosis, sustained virological response 12 weeks after the end of treatment (SVR12) was 97.4% and 96.7%, respectively, and rapid virological response (RVR) was 75.0% and 57.1%, respectively. SVR12 of GT3a, GT3b, and GT6a was 100%, 83.3%, and 97%, respectively. ALT normality rate in chronic hepatitis group is higher than that in cirrhosis group at 4 weeks of treatment (89.7% versus 60.0%, p = 0.033) and at 12 weeks after EOT (94.9% versus 66.7%, p = 0.021). The overall incidence rate of adverse events was 44.4%, with fatigue being the most common (13.0%). Conclusion. SOF-based DAAs regimen can achieve ideal SVR12 for Chinese patients with both GT3a and GT6a HCV infection. The tolerance and safety of SOF-based DAAs regimen are good.

Download Full-text